Author Affiliations: Retina Center, Minneapolis, Minnesota (Dr Bhavsar); Jaeb Center for Health Research, Tampa, Florida (Ms Stockdale and Mr Glassman); National Eye Institute, National Institutes of Health, Bethesda (Dr Ferris), and Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore (Dr Bressler), Maryland; and Scheie Eye Institute, Philadelphia, Pennsylvania (Dr Brucker).
Previously, the Diabetic Retinopathy Clinical Research Network reported a low rate of endophthalmitis achieved after intravitreal injection via a protocol requiring topical povidone-iodine, a sterile eyelid speculum, and topical anesthetic and not requiring topical antibiotics, sterile gloves, or a sterile drape.1 These results included 3838 injections of either ranibizumab or preservative-free triamcinolone acetonide. No antibiotics were given either before or after the injections in 1276 eyes. Of 3226 ranibizumab injections given between 2 Diabetic Retinopathy Clinical Research Network randomized trials, 3 cases of endophthalmitis occurred, all in eyes receiving topical antibiotics for several days after the injection.
Bhavsar AR, Stockdale CR, Ferris FL, Brucker AJ, Bressler NM, Glassman AR, Diabetic Retinopathy Clinical Research Network FT. Update on Risk of Endophthalmitis After Intravitreal Drug Injections and Potential Impact of Elimination of Topical Antibiotics. Arch Ophthalmol. 2012;130(6):809-810. doi:10.1001/archophthalmol.2012.227